Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
暂无分享,去创建一个
Robert Livingston | Lesley Seymour | Ming-Sound Tsao | Richard Inculet | L. Seymour | R. Livingston | D. Gandara | M. Tsao | K. Ding | J. Rigas | F. Shepherd | W. Fry | T. Demmy | Y. Cormier | C. Butts | D. Bethune | E. Vallières | G. Goss | Keyue Ding | K. Kesler | Timothy Winton | David Johnson | James Rigas | Michael Johnston | Charles Butts | Yvon Cormier | Glenwood Goss | Eric Vallieres | Willard Fry | Drew Bethune | Joseph Ayoub | Barbara Graham | David Gandara | Kenneth Kesler | Todd Demmy | Frances Shepherd | J. Ayoub | T. Winton | R. Inculet | M. Johnston | David H. Johnson | B. Graham
[1] G. Giaccone,et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. , 2003, Journal of the National Cancer Institute.
[2] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[3] S. Steinberg,et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.
[4] L. Seymour,et al. O-58 Quality of life in a trial of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer (NCIC CTG BR.10) , 2003 .
[5] M. Vangel,et al. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. , 2002, Lung cancer.
[6] M. Cullen. Lung cancer • 4: Chemotherapy for non-small cell lung cancer: the end of the beginning , 2003, Thorax.
[7] K. Kelly,et al. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] L. Seymour,et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. , 2005, Lung cancer.
[9] R. Gralla,et al. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[11] J. Soria,et al. Is cisplatin still the best platinum compound in non-small-cell lung cancer? , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[13] P Chomy,et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Minna,et al. Chemotherapy for non-small cell lung cancer , 1995, BMJ.
[15] A. Favero,et al. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis , 1992 .
[16] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[17] J. Mate,et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.
[18] M. Parmar,et al. Postoperative radiotherapy in non-small-cell lung cancer , 1998, The Lancet.
[19] A A Tsiatis,et al. Exact confidence intervals following a group sequential test. , 1984, Biometrics.
[20] Ron Brookmeyer,et al. A Confidence Interval for the Median Survival Time , 1982 .
[21] M. Tsao,et al. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] J G McVie,et al. Chemotherapy of non-small cell lung cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] R. Schilsky,et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Adak,et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. , 2000, The New England journal of medicine.
[25] R. Livingston,et al. [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer]. , 2001, Cancer Radiothérapie.
[26] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[27] J. Crowley,et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Jiroutek,et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] K. Sugimachi,et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.
[30] O. Brodin,et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .
[31] David E Morris,et al. Chemotherapeutic management of stage IV non-small cell lung cancer. , 2003, Chest.
[32] G. Giaccone,et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] C. Mountain,et al. Revisions in the International System for Staging Lung Cancer. , 1997, Chest.
[34] M. Parmar,et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.